Plasmalogens and Brain Aging: What the Evidence Shows

TL;DR: Plasmalogens are a class of phospholipid, a building block of every cell membrane, made in a cell part called the peroxisome and packed into the brain's myelin and nerve endings. They do two useful jobs: they act as a sacrificial shield against oxidative damage, and they carry the omega-3 fat DHA into brain tissue. Plasmalogen levels fall with age and fall further in Alzheimer's and Parkinson's, a well-replicated finding. What is not settled is whether losing plasmalogens helps drive the disease or is a byproduct of it, and whether taking a plasmalogen supplement changes how anyone's brain ages. The one sizable human trial missed its main goal while hinting at a benefit in a smaller subgroup, and the products are safe but unproven. Plasmalogens are worth watching, not worth betting your brain on ahead of sleep, exercise, cardiovascular risk, and omega-3s.

If you have run across plasmalogens on a longevity podcast or in a supplement pitch, this page explains what they are, why the biology is compelling, and why the human evidence is still thin enough that I hold the claims at arm's length. This is a topic where the science is honest and interesting, and the marketing tends to run ahead of it.

What are plasmalogens?

Every cell in your body is wrapped in a membrane built from phospholipids, molecules with a water-loving head and two fatty tails. Plasmalogens are a special version of that molecule. Where an ordinary phospholipid attaches both tails with a standard chemical link, a plasmalogen attaches one tail with an unusual bond called a vinyl-ether bond. That single difference is the whole story, because it gives plasmalogens two properties that ordinary membrane fats do not have.

First, that unusual bond is fragile in a useful way. When damaging molecules called free radicals tear through a membrane, they hit the plasmalogen's vinyl-ether bond first and burn out there, sparing the more important fats and proteins around it. The plasmalogen takes the hit so its neighbors do not. Second, plasmalogens preferentially hold DHA, the long-chain omega-3 fat that brain cells depend on, at their second tail position. That makes them one of the main ways the brain stores and delivers DHA to its own membranes.

Plasmalogens are most concentrated where the brain is most vulnerable to aging: the myelin that insulates nerve fibers and the tips of nerve cells where signals pass. They are also plentiful in heart and muscle.

Why do plasmalogens matter for the aging brain?

Two facts have pulled plasmalogens into the longevity conversation, and both hold up.

Plasmalogen levels drop as people get older, and they drop further in people with Alzheimer's disease and Parkinson's disease than in age-matched people without those conditions. This has been found again and again, in brain tissue studied after death and in the blood of living patients, by different research groups measuring in different ways.¹² One particular plasmalogen, the version carrying DHA, shows the most consistent decline. When a finding replicates across that many independent studies, the underlying biology is doing something.

There is also a telling natural experiment that proves plasmalogens are necessary for a healthy brain. Children born with genetic disorders that shut down plasmalogen production, called peroxisomal biogenesis disorders, have severe neurological disease from birth.³ That tells us the body cannot do without plasmalogens. It does not, on its own, tell us that the milder decline seen in ordinary aging is a cause of dementia rather than a passenger of it. That gap is the crux of the whole topic.

Does plasmalogen depletion cause dementia, or just come along with it?

This is the question that decides whether plasmalogens are a lever worth pulling. There are two honest ways to read the data, and the science has not settled between them.

One reading is that low plasmalogens help drive the damage. Fewer plasmalogens mean less of that sacrificial shield against oxidative stress and less DHA delivered to nerve membranes, which could leave the brain more exposed to the insults that accumulate into dementia. If that is right, raising plasmalogens early might protect the brain.

The other reading is that low plasmalogens are a record of the damage rather than its cause. The same oxidative and inflammatory processes that drive Alzheimer's would consume plasmalogens as they burn, so a low level would be smoke rather than fire. If that is right, topping plasmalogens back up would move a number on a lab report without changing anyone's trajectory.

Both stories fit the evidence we have, and probably some of both is true. Until studies can follow people from before symptoms start, or use genetics to test cause directly, the direction of the arrow stays open. I would not spend money or hope on the assumption that it points the helpful way.

Can you take a plasmalogen supplement, and does it work?

You can buy plasmalogen supplements, usually made from scallops or from shark-liver oils, and newer ones made to deliver DHA-carrying plasmalogens directly. The honest state of the evidence is that they are safe and unproven.

The one sizable human trial is worth understanding, because it is often described as either a win or a flop when it was neither. In a 2017 study, 328 people aged 60 to 85 with mild Alzheimer's or mild cognitive impairment took either 1 mg per day of a scallop-derived plasmalogen or a placebo for 24 weeks.⁴ The trial missed its main goal: across the whole group, memory scores did not separate from placebo by the pre-set bar. In the smaller subgroup with mild Alzheimer's, memory scores did improve on treatment, and the difference between groups came close to statistical significance without quite reaching it. Blood plasmalogen levels rose, and there was no safety signal. The fair summary is that the supplement did something measurable to the biology and hinted at a memory benefit in one subgroup, which is enough to justify bigger trials and not enough to call it effective.

A smaller 2022 study of a DHA-plasmalogen precursor reported mixed cognitive results and rising blood plasmalogen levels, but it had no placebo group, so it can show that the pill reaches the target without showing that reaching the target helps.⁵ No large, well-controlled trial has shown that plasmalogen supplements change how anyone's brain ages, and none of these products is approved by the FDA to treat or prevent any condition.

If I already take fish oil, do I need plasmalogens?

This is the most interesting practical wrinkle, and it is worth understanding even while the evidence is early. The omega-3 index, the standard blood test for fish-oil status, measures DHA and EPA riding in your red blood cells. It does not measure the plasmalogen scaffolds that carry DHA into brain tissue. In theory, someone could take plenty of fish oil, post a healthy omega-3 index, and still deliver less DHA into brain membranes if their plasmalogen production has fallen off with age.

That is a plausible mechanism, and it may be one reason large fish-oil trials for cognition have produced smaller and less consistent results than the observational data predicted. It is not a reason to stop fish oil, which has its own evidence for heart and general health, and it is not yet a proven reason to add a plasmalogen product on top. It is a reason to keep an eye on this field.

How Fishtown Medicine reads plasmalogens

I treat plasmalogens the way I treat most promising, early longevity science: interested, honest, and unhurried. The biology is sound and well-mapped, the decline with aging and disease is well-documented, and the intervention evidence is not there yet. That combination calls for watching closely, not buying in ahead of the data.

For a patient worried about their brain, the levers that already have strong evidence come first, and they are not exotic: sleep you protect, regular aerobic and strength exercise, blood pressure and ApoB kept in range, blood sugar managed, hearing loss corrected, social connection, and adequate omega-3 intake. Those move the needle on cognitive aging today. If someone has a strong family history or is already pursuing an aggressive brain-protection plan and wants to consider plasmalogens, the sensible way to do it is to measure a baseline, treat it as an experiment rather than a cure, and track whether anything changes, rather than swallowing an expensive pill on faith. Whether you are in Fishtown or Fitler Square, I would rather spend your effort and money where the evidence already is and revisit plasmalogens as the trials mature.

Guidance from the Clinic

"Plasmalogens are a good example of how I try to hold early science. The biology is elegant and the decline in Alzheimer's has been found over and over, so I take it seriously. But the one sizable trial missed its main mark, and I have watched too many beautiful mechanisms fail to help people to promise a patient that a supplement will protect their memory. So I tell people the truth: this is worth watching, it is safe, and it is unproven. Then we spend the appointment on the things that already protect the aging brain, because those are the ones I can stand behind."

Related at Fishtown Medicine

• Biological Age Testing - measuring how fast you are aging, and the limits of those tests
• NAD+ vs. AG1: Separating the Science from the Hype - another longevity supplement held up to the evidence
• Brain Health - the levers that protect cognition with evidence behind them
• Omega-3 Index - the standard test for fish-oil status, and what it does and does not measure
• Blood Test for Alzheimer's (p-tau217) - a newer marker with a clearer evidence base

Scientific References

1. Goodenowe DB, Cook LL, Liu J, et al. "Peripheral ethanolamine plasmalogen deficiency: a logical causative factor in Alzheimer's disease and dementia." Journal of Lipid Research. 2007;48(11):2485-2498.
2. Su XQ, Wang J, Sinclair AJ. "Plasmalogens and Alzheimer's disease: a review." Lipids in Health and Disease. 2019;18(1):100.
3. Braverman NE, Moser AB. "Functions of plasmalogen lipids in health and disease." Biochimica et Biophysica Acta. 2012;1822(9):1442-1452.
4. Fujino T, Yamada T, Asada T, et al. "Efficacy and blood plasmalogen changes by oral administration of plasmalogen in patients with mild Alzheimer's disease and mild cognitive impairment: a multicenter, randomized, double-blind, placebo-controlled trial." EBioMedicine. 2017;17:199-205.
5. Smith RG, Goodenowe DB, Dayan A, et al. "Targeted plasmalogen supplementation: effects on blood plasmalogens, oxidative stress biomarkers, cognition, and mobility in cognitively impaired persons." Frontiers in Cell and Developmental Biology. 2022;10:864842.
6. Werner ER, Keller MA, Sailer S, et al. "The TMEM189 gene encodes plasmanylethanolamine desaturase which introduces the characteristic vinyl ether double bond into plasmalogens." Proceedings of the National Academy of Sciences. 2020;117(14):7792-7798.